ArticleMetabolic brain disease2026
Neuroprotective effects of myrtenol against brain injury following isoproterenol-induced myocardial infarction in male rats.
Article in Metabolic brain disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myocardial infarction (MI) induces brain injury. Myrtenol has antioxidant and anti-inflammatory effects. This study investigated the neuroprotective effect of myrtenol following myocardial infarction induced by isoproterenol (ISO) in male rats. This experimental study involved 36 male Wistar rats. They were divided into six groups. Rats received ISO (85 mg/kg) for two days. Subsequently, they were treated with vehicle or myrtenol (5, 25, or 50 mg/kg) once daily, one hour after the last ISO injection, for seven days. Behavioral tests (spontaneous alternation and passive avoidance) were conducted post-treatment. Hemodynamic parameters and serum troponin were assessed. Tissue samples (heart/brain tissue) underwent histopathological examination via H&E and Nissl staining methods. The activities of glutathione peroxidase (GPx), catalase, and superoxide dismutase (SOD), along with malondialdehyde (MDA) content and total antioxidant capacity (TAC) were measured in heart and brain tissue. Western blot analysis was used for the assessment of inflammatory (TNF and NF-κB), cell death (Bax, Bcl2, and Cleaved caspase-3), and nuclear factor erythroid-related factor-2 (Nrf2) markers in brain tissue. ISO significantly reduced latency time and spontaneous alternation compared to control (p < 0.001). Myrtenol improved these parameters at 25 mg/kg (p < 0.01) and 50 mg/kg (p < 0.001). Myrtenol also reduced MDA content, Bax, Cleaved caspase-3, TNF, and NF-κB protein expression and also increased Bcl2, and Nrf2 proteins, TAC level, SOD, GPx, and catalase enzyme activity in heart/brain tissues when compared to ISO group (p < 0.05). Myrtenol improved memory function and hemodynamic parameters. It decreases brain oxidative stress, inflammation and cell death markers, highlighting its potential as a therapeutic agent.
Indexed as
Identifiers
42159792What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.